Condensed Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Notes [Member]	Series C-1 Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series C-1 Preferred Stock [Member]	Preferred Stock [Member] Series C-2 Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Notes [Member]	Additional Paid-in Capital [Member] Series C-1 Preferred Stock [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member] Series A Preferred Stock [Member]	Accumulated Deficit [Member] Series C-1 Preferred Stock [Member]	Accumulated Deficit [Member] Series C-2 Preferred Stock [Member]
Beginning Balance at Dec. 31, 2021	$ (29,577,046)						$ 2,272		$ 3,195,138			$ (32,774,456)
Beginning Balance (in Shares) at Dec. 31, 2021							2,272,111
Temporary equity accretion of dividends during the period				$ (230,942)	$ (304)	$ (16,906)							$ (230,942)	$ (304)	$ (16,906)
Issuance of common stock for service	26,477						$ 13		26,464
Issuance of common stock for service (in Shares)							12,534
Exercise of common stock purchase warrants	16,659						$ 9		16,650
Exercise of common stock purchase warrants (in Shares)							9,321
Warrants issued in connection with notes/preferred stock		$ 409,483	$ 92,055							$ 409,483	$ 92,055
Repurchase of common stock	(2,294)							$ (2,294)
Repurchase of common stock (in Shares)								1,411,825
Cancellation of common stock							$ (1,412)	$ 2,294	(882)
Cancellation of common stock (in Shares)							(1,411,825)	(1,411,825)
Stock-based compensation expense	449,817								449,817
Net loss	(5,936,114)											(5,936,114)
Ending Balance at Sep. 30, 2022	(34,769,115)						$ 882		4,188,725			(38,958,722)
Ending Balance (in Shares) at Sep. 30, 2022							882,141
Beginning Balance at Jun. 30, 2022	(28,821,777)						$ 1,803		3,973,650			(32,797,230)
Beginning Balance (in Shares) at Jun. 30, 2022							1,803,045
Temporary equity accretion of dividends during the period				(76,980)	(304)	(16,906)							(76,980)	(304)	(16,906)
Exercise of common stock warrants	16,659						$ 9		16,650
Exercise of common stock warrants (in Shares)							9,321
Warrants issued in connection with notes/preferred stock			$ 92,055								$ 92,055
Repurchase of common stock	(1,511)							$ (1,511)
Repurchase of common stock (in Shares)								930,225
Cancellation of common stock							$ (930)	$ 1,511	(581)
Cancellation of common stock (in Shares)							(930,225)	(930,225)
Stock-based compensation expense	106,951								106,951
Net loss	(6,067,302)											(6,067,302)
Ending Balance at Sep. 30, 2022	(34,769,115)						$ 882		4,188,725			(38,958,722)
Ending Balance (in Shares) at Sep. 30, 2022							882,141
Beginning Balance at Dec. 31, 2022	(37,790,539)						$ 894		4,590,858			(42,382,291)
Beginning Balance (in Shares) at Dec. 31, 2022							894,318
Temporary equity accretion of dividends during the period				(164,510)	(40,551)	(470,962)							(164,510)	(40,551)	(470,962)
Exercise of common stock options	$ 41,064						$ 14		41,050
Exercise of common stock options (in Shares)	23,420						23,420
Warrants issued in connection with notes/preferred stock		$ 55,062								$ 55,062
Common stock issued to convertible noteholder at the Merger	$ 250,000						$ 3		249,997
Common stock issued to convertible noteholder at the Merger (in Shares)							25,000
Business Combination with Alpha, net of transaction costs	55,382,355						$ 1,013		55,381,342
Business Combination with Alpha, net of transaction costs (in Shares)							18,302,510
Common and Series A Preferred stock issued in conjuction with AxBio Acquisition	21,652,790			$ 1			$ 385		21,652,404
Common and Series A Preferred stock issued in conjuction with AxBio Acquisition (in Shares)				4,243			3,845,337
Stock-based compensation expense	605,299								605,299
Net loss	(18,602,436)											(18,602,436)
Ending Balance at Sep. 30, 2023	20,917,571			$ 1			$ 2,308		82,576,012			(61,660,750)
Ending Balance (in Shares) at Sep. 30, 2023				4,243			23,090,585
Beginning Balance at Jun. 30, 2023	(45,106,381)						$ 908		5,039,314			(50,146,603)
Beginning Balance (in Shares) at Jun. 30, 2023							908,795
Temporary equity accretion of dividends during the period				$ (12,655)	$ (2,912)	$ (33,811)							$ (12,655)	$ (2,912)	$ (33,811)
Exercise of common stock options	15,195								15,195
Exercise of common stock options (in Shares)							8,943
Common stock issued to convertible noteholder at the Merger	250,000						$ 3		249,997
Common stock issued to convertible noteholder at the Merger (in Shares)							25,000
Business Combination with Alpha, net of transaction costs	55,382,355						$ 1,013		55,381,342
Business Combination with Alpha, net of transaction costs (in Shares)							18,302,510
Common and Series A Preferred stock issued in conjuction with AxBio Acquisition	21,652,790			$ 1			$ 385		21,652,404
Common and Series A Preferred stock issued in conjuction with AxBio Acquisition (in Shares)				4,243			3,845,337
Stock-based compensation expense	237,760								237,760
Net loss	(11,464,769)											(11,464,769)
Ending Balance at Sep. 30, 2023	$ 20,917,571			$ 1			$ 2,308		$ 82,576,012			$ (61,660,750)
Ending Balance (in Shares) at Sep. 30, 2023				4,243			23,090,585